IDRI Announces $11.9M Contract to Develop Thermostable TB Vaccine

November 19th, 2014|Press Releases|

Seattle, WA | November 19, 2014 FOR IMMEDIATE RELEASE: SEATTLE, Nov. 19, 2014: With the goal of developing a thermostable tuberculosis vaccine that is resistant to damage from excessive heat or cold, IDRI (Infectious Disease Research Institute) today announces [...]

IDRI Named Outstanding Global Health Organization by WGHA

August 25th, 2014|Press Releases|

Seattle, WA | August 25, 2014 FOR IMMEDIATE RELEASE: SEATTLE, Aug. 25, 2014: IDRI (Infectious Disease Research Institute) has been named as the recipient of the inaugural Outstanding Global Health Organization award, presented by the Washington Global Health Alliance [...]

IDRI’s Rhea Coler Recognized as Recipient of “Women to Watch in Life Science” Award

June 10th, 2014|Press Releases|

Seattle, WA | June 10, 2014 FOR IMMEDIATE RELEASE: SEATTLE, March 24, 2014: Rhea Coler, Ph.D., Vice President of Preclinical Biology for IDRI (Infectious Disease Research Institute), has been named as a recipient of the “Women to Watch in [...]

IDRI Receives $3.4M Grant Extension for TB Drug Discovery

March 24th, 2014|Press Releases|

Seattle, WA | March 24, 2014 FOR IMMEDIATE RELEASE: SEATTLE, March 24, 2014: IDRI's drug discovery efforts continue to grow with a recently awarded grant extension of $3.4 million from the Bill & Melinda Gates Foundation. The additional funding [...]

IDRI Announces Evolution of Leadership Roles

December 19th, 2013|Press Releases|

Seattle, WA | December 19, 2013 As IDRI’s 20th year comes to a productive close with diagnostics on the market, vaccines in clinical trials, and drugs being discovered for the world’s most devastating infectious diseases, the organization today announced [...]

IDRI and Zydus Sign Agreement for Development of IDRI’s Vaccine Candidate for Visceral Leishmaniasis (Kala-Azar)

July 25th, 2013|Press Releases|

Seattle, WA | July 25, 2013 Seattle, WA, and Ahmedabad, India, July 25, 2013: – In a unique partnership, Zydus, India’s fourth largest healthcare group and an innovation-led global healthcare provider, and IDRI, a Seattle-based non-profit research and product [...]

IDRI Moves into New Space at 1616 Eastlake

May 7th, 2013|Press Releases|

Seattle, WA | May 7, 2013 Seattle, WA, May 7, 2013: IDRI (Infectious Disease Research Institute) has officially moved from its long-time residence in Seattle’s First Hill neighborhood to its new home at 1616 Eastlake Avenue East, where it [...]

IDRI and Medicago Report Positive Results for Phase 1 Clinical Trial for an H5N1 Vaccine

April 17th, 2013|Press Releases|

Seattle, WA | April 17, 2013 SEATTLE, WA, and QUEBEC CITY, QC, April 17, 2013 – IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, [...]

IDRI and Medicago to Present Data at the World Vaccine Congress

April 8th, 2013|Press Releases|

Seattle, WA | April 8, 2013 SEATTLE, WA, and QUEBEC CITY, QC, April 9, 2013 – IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, [...]

IDRI and Orangelife Register Rapid Diagnostic for Leprosy for Use in Brazil

January 24th, 2013|Press Releases|

Seattle, WA | January 24, 2013 IDRI (Infectious Disease Research Institute), in conjunction with OrangeLife, a Brazilian diagnostic company, today announces the registration of a rapid diagnostic test for leprosy, offering new hope for early diagnosis and treatment. The [...]

Load More